📅 The #ESTROSchool Calendar for the 2024 Teaching Courses is now AVAILABLE!
Explore our 32 post-graduate courses, designed for all disciplines of RT: https://t.co/EfCn5HeKHX
👉Register for live or online courses, tailored to elevate your expertise: https://t.co/mCk4syw2d0 #MedEd
Further evidence on the causal relation between heart irradiation and survival of lung cancer from Odense with collaboration from @TheChristieNHS@RT_physics https://t.co/d4WZQPqkLg
Manuscript drafts 📝
Peer reviews 📑
Emails 📧
Academia is notorious for being late
How to stick to a writing deadline
A thread🧵
@AcademicChatter@PhD_Genie@OpenAcademics
Its an insurmountable task for many seniors in academia to keep up with emails. The recommendations from @LNivisonSmith are formidable.
Thanks for the retweet @stinekorreman
As a PhD student, my supervisor never answered my emails.
Then I became a PhD supervisor and realised why
A thread🧵 of my mistakes and how to avoid them
#phdchat#AcademicTwitter
Yes! #RTTs need to be involved in clinical trial - preferably from the start.
Our RCT for MSCC ESO-spare is based on data from RTT Vanja Remberg Gram’s RTT project
That was initiated together with #medphys@LotteSFog 💪
Congratulations to @ESTRO_RT for electing a(n) (honorary) physicist for president🙌
Well deserved honor to the incredibly hard working and excellent @Mat_Guc who has contributed in so many ways to the #radonc society.
#ESTRO2022#ESTRO22
Congrats to @Mat_Guc for being elected as @ESTRO_RT president (elect, for the moment)
@AnnaKirby17 becomes president for 2 years, & @bslotman past president.
Thanks to the three of them for all they do for the Society & #radonc community at large.
🙏🙏🙏🙏🙏🙏🙏🙏🙏🙏🙏🙏🙏
Well done @FelterMette💪 Nice presentation of target characteristics from the multicenter SOFT trial of MR-guided SBRT of infra-diafragmatic soft tissue oligo mets. Early tox data are soon mature @IvanVogelius @TineSchytte@radoncbme@MettePoel@MirjanaMedPhys and many more
@SrenMller14 presented real world data on >1300 patients receiving SRS/SRT for brain metastases. More data comming soon. Great collaboration between neighbouring institutions @Rigshospitalet@HerlevGentofte#ESTRO2022
So proud of Nicklas Spindler, who presented our very first data from the Bony-M trial of SBRT for bony OMD with patients from Denmark and Norway @FelterMette@MSuppli@laurids_poulsen med flere
@azza64@Mat_Guc The OligoCare study will greatly help the enormous knowledge gap in OMD💪
I wonder if the significant difference between applied dose to CRC and BC, LC & PC reflect upon the different metastatic pattern = represents different lesion locations?